Identification of p53 and its isoforms in human breast carcinoma cells

The Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Milićević, Zorka ^a   Bajić, Vladan ^b   Živković, Lada ^c   Kasapović, Jelena ^a   Andjelković, Uroš ^c   Spremo Potparević, Biljana ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Researcher Institute Go a   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXIDASE; PROTEIN P53; ISOPROTEIN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MIDDLE AGED; NUCLEOLUS; OVERALL SURVIVAL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; WESTERN BLOTTING; AGED; BREAST TUMOR; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PROTEIN TRANSPORT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; PROTEIN ISOFORMS; PROTEIN TRANSPORT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893205816     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/618698     Document Type: Article

References (63)

1. Vousden K. H., Prives C., Blinded by the light: the growing complexity of p53. Cell 2009 137 3 413 431 2-s2.0-65349103899 10.1016/j.cell.2009.04.037
2. Royds J. A., Iacopetta B., p53 and disease: when the guardian angel fails. Cell Death and Differentiation 2006 13 6 1017 1026 2-s2.0-33646782954 10.1038/sj.cdd.4401913
3. Soong R., Iacopetta B. J., Harvey J. M., Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. International Journal of Cancer 1997 4 642 647 (Pubitemid 28037509)
4. Norberg T., Klaar S., Kärf G., Nordgren H., Holmberg L., Bergh J., Increased p53 mutation frequency during tumor progression-Results from a breast cancer cohort. Cancer Research 2001 61 22 8317 8321 2-s2.0-0035890360 (Pubitemid 33091627)
5. Anensen N., Oyan A. M., Bourdon J.-C., Kalland K. H., Bruserud O., Gjertsen B. T., A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research 2006 12 13 3985 3992 2-s2.0-33746064087 10.1158/1078-0432.CCR-05-1970 (Pubitemid 44078084)
6. Miller L. D., Smeds J., George J., Vega V. B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E. T., Bergh J., An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proceedings of the National Academy of Sciences of the United States of America 2005 102 38 13550 13555 2-s2.0-26444546442 10.1073/pnas.0506230102 (Pubitemid 41420886)
7. Murray-Zmijewski F., Lane D. P., Bourdon J.-C., p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death and Differentiation 2006 13 6 962 972 2-s2.0-33646798450 10.1038/sj.cdd.4401914
8. Marcel V., Hainaut P., p53 isoforms-a conspiracy to kidnap p53 tumor suppressor activity? Cellular and Molecular Life Sciences 2009 66 3 391 406 2-s2.0-59349099726 10.1007/s00018-008-8336-3
9. Ward A. J., Cooper T. A., The pathobiology of splicing. Journal of Pathology 2010 220 2 152 163 2-s2.0-73949128867 10.1002/path.2649
10. Murray-Zmijewski F., Slee E. A., Lu X., A complex barcode underlies the heterogeneous response of p53 to stress. Nature Reviews Molecular Cell Biology 2008 9 9 702 712 2-s2.0-50149097809 10.1038/nrm2451
11. Midgley C. A., Fisher C. J., Bartek J., Vojtesek B., Lane D., Barnes D. M., Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. Journal of Cell Science 1992 101 1 183 189 2-s2.0-0026569616
12. Sobin L. H., Wittekind C. H., TNM Classification of Malignant Tumors 1997 5th International Union Against Cancer (UICC) New York, NY, USA John Wiley & Sons
13. Blobel G., Potter V. R., Nuclei from rat liver: isolation method that combines purity with high yield. Science 1966 154 757 1662 1665 2-s2.0-0014032729
14. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry 1951 193 1 265 275 2-s2.0-71849104860
15. Laemmli U. K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970 227 5259 680 685 2-s2.0-0014949207 10.1038/227680a0
16. Towbin H., Staehelin T., Gordon J., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences of the United States of America 1979 76 9 4350 4354 2-s2.0-0009482260 (Pubitemid 9256559)
17. Hsu S. M., Raine L., Fanger H., Use of Avidin-Biotin-Peroxidase Complex (ABC) in Immunoperoxidase Techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. Journal of Histochemistry and Cytochemistry 1981 29 4 577 580 2-s2.0-0019423594 (Pubitemid 11147380)
18. Vojtesek B., Bartek J., Midgley C. A., Lane D. P., An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. Journal of Immunological Methods 1992 151 1-2 237 244 2-s2.0-0026769713 10.1016/0022-1759(92)90122-A
19. cordell J. L., Falini B., Erber W. N., Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). Journal of Histochemistry and Cytochemistry 1984 32 2 219 229 2-s2.0-0021331061 (Pubitemid 14184314)
20. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S. V., Hainaut P., Olivier M., Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutation 2007 28 6 622 629 2-s2.0-34248379012 10.1002/humu.20495 (Pubitemid 46744292)
21. Heinlein C., Krepulat F., Löhler J., Speidel D., Deppert W., Tolstonog G. V., Mutant p53R270H gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. International Journal of Cancer 2008 122 8 1701 1709 2-s2.0-40349087171 10.1002/ijc.23317 (Pubitemid 351413415)
22. Adhikari A. S., Iwakuma T., Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications. Fukuoka Igaku Zasshi 2009 100 6 217 228 2-s2.0-70349334720
23. Muller P. A. J., Caswell P. T., Doyle B., Iwanicki M. P., Tan E. H., Karim S., Lukashchuk N., Gillespie D. A., Ludwig R. L., Gosselin P., Cromer A., Brugge J. S., Sansom O. J., Norman J. C., Vousden K. H., Mutant p53 drives invasion by promoting integrin recycling. Cell 2009 139 7 1327 1341 2-s2.0-72249100428 10.1016/j.cell.2009.11.026
24. Brosh R., Rotter V., When mutants gain new powers: news from the mutant p53 field. Nature Reviews Cancer 2009 9 10 701 713 2-s2.0-70349443284 10.1038/nrc2693
25. Oren M., Rotter V., Mutant p53 gain-of-function in cancer. Cold Spring Harbor Perspectives in Biology 2010 2 2 a001107 2-s2.0-77950521214 10.1101/cshperspect.a001107
26. Al-Joudi F. S., Iskandar Z. A., Rusli J., The expression of p53 in invasive ductal carcinoma of the breast: a study in the North-East States of Malaysia. Medical Journal of Malaysia 2008 63 2 96 99 2-s2.0-55049101253
27. Olivier M., Langerød A., Carrieri P., Bergh J., Klaar S., Eyfjord J., Theillet C., Rodriguez C., Lidereau R., Bièche I., Varley J., Bignon Y., Uhrhammer N., Winqvist R., Jukkola-Vuorinen A., Niederacher D., Kato S., Ishioka C., Hainaut P., Børresen-Dale A.-L., The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clinical Cancer Research 2006 12 4 1157 1167 2-s2.0-33644772215 10.1158/1078-0432.CCR-05- 1029 (Pubitemid 43342504)
28. Shah S. P., Roth A., Goya R., The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012 486 395 399
29. Thor A. D., Moore D. H. II, Edgerton S. M., Kawasaki E. S., Reihsaus E., Lynch H. T., Marcus J. N., Schwartz L., Chen L.-C., Mayall B. H., Smith H. S., Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. Journal of the National Cancer Institute 1992 84 11 845 855 2-s2.0-0026724877
30. Isola J., Visakorpi T., Holli K., Kallioniemi O.-P., Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. Journal of the National Cancer Institute 1992 84 14 1109 1114 2-s2.0-0026659891
31. Molina R., Segui M. A., Climent M. A., Bellmunt J., Albanelll J., Fernandez M., Filella X., Jo J., Gimenez N., Iglesias E., Miralles M., Alonso C., Peiro G., Perez-Picañol E., Ballesta A. M., p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Research 1998 18 1 B 507 511 2-s2.0-15444353870 (Pubitemid 28174864)
32. Weigelt B., Peterse J. L., Van't Veer L. J., Breast cancer metastasis: markers and models. Nature Reviews Cancer 2005 5 8 591 602 2-s2.0-23144442644 10.1038/nrc1670 (Pubitemid 41081385)
33. Nicolini A., Carpi A., Tarro G., Biomolecular markers of breast cancer. Frontiers in Bioscience 2006 11 2 1818 1843 2-s2.0-32844457528 (Pubitemid 43253397)
34. Nicolini A., Ferrari P., Cavazzana A., Carpi A., Berti P., Miccoli P., Conventional and new emerging prognostic factors in breast cancer: an update. Biomarkers in Medicine 2007 1 525 540
35. Riethdorf S., Wikman H., Pantel K., Review: biological relevance of disseminated tumor cells in cancer patients. International Journal of Cancer 2008 123 9 1991 2006 2-s2.0-51649120140 10.1002/ijc.23825
36. Mazars R., Spinardi L., BenCheikh M., Simony-Lafontaine J., Jeanteur P., Theillet C., p53 Mutations occur in aggressive breast cancer. Cancer Research 1992 52 14 3918 3923 2-s2.0-0026638007
37. Pharaoh P. D. P., Day N. E., Caldas C., Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. British Journal of Cancer 1999 80 12 1968 1973 2-s2.0-0032814777 10.1038/sj.bjc.6690628 (Pubitemid 29391282)
38. Geisler S., Lønning P. E., Aas T., Johnsen H., Fluge Ø., Haugen D. F., Lillehaug J. R., Akslen L. A., Børresen-Dale A.-L., Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Research 2001 61 6 2505 2512 2-s2.0-0035866772 (Pubitemid 32685830)
39. Soussi T., Béroud C., Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Reviews Cancer 2001 1 3 233 240 2-s2.0-0035751937 (Pubitemid 33741898)
40. Ho G. H., Calvano J. E., Bisogna M., In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer 2000 89 2153 2160
41. Done S. J., Eskandarian S., Bull S., Redston M., Andrulis I. L., P53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. Journal of the National Cancer Institute 2001 93 9 700 704 2-s2.0-0035795630 (Pubitemid 32492811)
42. Done S. J., Arneson N. C. R., Özçelik H., Redston M., Andrulis I. L., p53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers. Breast Cancer Research and Treatment 2001 65 2 111 118 2-s2.0-0035127784 10.1023/A:1006425809069 (Pubitemid 32193614)
43. Hill K. A., Sommer S. S., p53 as a mutagen test in breast cancer. Environmental and Molecular Mutagenesis 2002 39 2-3 216 227 2-s2.0-0036202781 10.1002/em.10065 (Pubitemid 34260496)
44. Sorlie T., Borresen-Dale A. L., Lonning P. E., Brown P. O., Botstein D., Brenner C., Duggan D. J., Expression profiling of breast cancer: from molecular portraits to clinical utility. Oncogenomics: Molecular Approaches to Cancer 2003 Hoboken, NJ, USA JohnWiley and Sons 10.1002/047147665X.ch5
45. Davidoff A. M., Kerns B.-J. M., Iglehart J. D., Marks J. R., Maintenance of p53 alterations throughout breast cancer progression. Cancer Research 1991 51 10 2605 2610 2-s2.0-0025817813
46. Greenblatt M. S., Grollman A. P., Harris C. C., Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Research 1996 56 9 2130 2136 2-s2.0-0029996282 (Pubitemid 26119914)
47. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M., Harris C. C., Montesano R., IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Research 1998 26 1 205 213 2-s2.0-0031841384 10.1093/nar/26.1.205 (Pubitemid 28291534)
48. Zhou X., Wang X. W., Xu L., Hagiwara K., Nagashima M., Wolkowicz R., Zurer I., Rotter V., Harris C. C., COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Research 1999 59 4 843 848 2-s2.0-0345059361 (Pubitemid 29086737)
49. Scheer U., Hock R., Structure and function of the nucleolus. Current Opinion in Cell Biology 1999 11 3 385 390 2-s2.0-0033153298 10.1016/S0955- 0674(99)80054-4 (Pubitemid 29273811)
50. Opferman J. T., Zambetti G. P., Translational research? Ribosome integrity and a new p53 tumor suppressor checkpoint. Cell Death and Differentiation 2006 13 6 898 901 2-s2.0-33646817102 10.1038/sj.cdd.4401923
51. Sundqvist A., Liu G., Mirsaliotis A., Xirodimas D. P., Regulation of nucleolar signalling to p53 through NEDDylation of L11. EMBO Reports 2009 10 10 1132 1139 2-s2.0-70449697971 10.1038/embor.2009.178
52. Straus B. E., Haas M., The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant p53 proteins. Biochemical and Biophysical Research Communications 1995 217 1 333 340 2-s2.0-0029587415 10.1006/bbrc.1995.2781 (Pubitemid 26004796)
53. Deppert W., Binding of MAR-DNA elements by mutant p53: possible implications for its oncogenic functions. Journal of Cellular Biochemistry 1996 62 172 180 (Pubitemid 26287201)
54. Will K., Warnecke G., Albrechtsen N., Boulikas T., Deppert W., High affinity MAR-DNA binding is a common property of murine and human mutant p53. Journal of Cellular Biochemistry 1998 69 260 270 (Pubitemid 28227703)
55. Will K., Warnecke G., Wiesmüller L., Deppert W., Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing. Proceedings of the National Academy of Sciences of the United States of America 1998 95 23 13681 13686 2-s2.0-0032506229 10.1073/pnas.95.23.13681 (Pubitemid 28523032)
56. Wynford-Thomas D., Blaydes J., The influence of cell context on the selection pressure for p53 mutation in human cancer. Carcinogenesis 1998 19 1 29 36 2-s2.0-0031815216 10.1093/carcin/19.1.29 (Pubitemid 28376822)
57. Bourdon J.-C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., Xirodimas D. P., Saville M. K., Lane D. P., p53 isoforms can regulate p53 transcriptional activity. Genes and Development 2005 19 18 2122 2137 2-s2.0-24344448786 10.1101/gad.1339905 (Pubitemid 41330315)
58. Ghosh A., Stewart D., Matlashewski G., Regulation of human p53 activity and cell localization by alternative splicing. Molecular and Cellular Biology 2004 24 18 7987 7997 2-s2.0-4444351219 10.1128/MCB.24.18.7987-7997.2004 (Pubitemid 39167449)
59. Hollstein M., Hainaut P., Massively regulated genes: the example of TP53. Journal of Pathology 2010 220 2 164 173 2-s2.0-73949117703 10.1002/path.2637
60. Rohaly G., Chemnitz J., Dehde S., Nunez A. M., Heukeshoven J., Deppert W., Dornreiter I., A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 2005 122 1 21 32 2-s2.0-22144463164 10.1016/j.cell.2005.04.032 (Pubitemid 40977937)
61. Wan M. C., Poon R. Y. C., The p53 isoform Δp53 lacks intrinsic transcriptional activity and reveals the critical role of nuclear import in dominant-negative activity. Cancer Research 2007 67 5 1959 1969 2-s2.0-33947254018 10.1158/0008-5472.CAN-06-3602 (Pubitemid 46424212)
62. Fujita K., Mondal A. M., Horikawa I., p53 isoforms Δ133p53 and p53 β are endogenous regulators of replicative cellular senescence. Nature Cell Biology 2009 11 1135 1142
63. Bourdon J.-C., Khoury M. P., Diot A., Baker L., Fernandes K., Aoubala M., Quinlan P., Purdie C. A., Jordan L. B., Prats A.-C., Lane D. P., Thompson A. M., P53 mutant breast cancer patients expressing p53 γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Research 2011 13 1, article R7 2-s2.0-84860390553 10.1186/bcr2811